Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.22.56 (
caspase-3
)
35,750
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Background:
Long non-coding RNA Zinc finger E-box binding homeobox 2 (ZEB2) antisense RNA 1 (
ZEB2-
AS1
) has been shown to promote tumor progression. However, the clinical significance and fundamental function role of
ZEB2-
AS1
in osteosarcoma (OS) was poorly understood.
Methods:
The expression of
ZEB2-
AS1
was determined in tumor tissues and matched normal tissues from 67 OS patients using quantitative reverse transcriptase PCR analysis. Clinical value of
ZEB2-
AS1
was evaluated by Chi square test and Kaplan-Meier method. Cell proliferation was analyzed using CCK-8 assay, colony formation. Cell apoptosis status was determined by
caspase-3
activity assay. Cell migration, invasion and epithelial-mesenchymal transition (EMT) were investigated by scratch wound healing, transwell invasion assays and western blotting.
Results:
Clinical association analysis revealed that high
ZEB2-
AS1
expression correlated with tumor size, distant metastasis and poor prognosis of OS patients. Moreover,
ZEB2-
AS1
expression was identified as an independent prognostic factor for OS patients. Loss-of-function assays demonstrated that
ZEB2-
AS1
knockdown suppressed the proliferation and induced apoptosis in OS cells. In addition,
ZEB2-
AS1
knockdown inhibited cell migration, invasion, EMT of OS cells
in vitro
.
Conclusions:
Taken together, our data demonstrate that
ZEB2-
AS1
serves a putative oncogenic role and associates with unfavorable prognosis in OS.
...
PMID:The Long Noncoding RNA
ZEB2-AS1
Contributes to Proliferation and Epithelial-to-Mesenchymal Transition of Osteosarcoma. 3308 24
Previous studies suggest the tumor suppressor role of long non-coding RNA (lncRNA) STXBP5-
AS1
in cervical and gastric cancer, but its expression pattern and functional mechanism are still elusive in pancreatic cancer (PC). Relative expression of STXBP5-
AS1
in PC both in vivo and in vitro was analyzed by real-time PCR. IC
50
of Gemcitabine was determined by the MTT assay. Cell proliferation in response to drug treatment was investigated by colony formation assay. Cell apoptosis was measured by both
caspase-3
activity and Annexin V/PI staining. Cell invasion capacity was scored by the transwell assay in vitro, and lung metastasis was examined with the tail vein injection assay. Cell stemness was determined in vitro by sphere formation and marker profiling, respectively, and in vivo by limited dilution of xenograft tumor incidence. Subcellular localization of STXBP5-
AS1
was analyzed with fractionation PCR. Association between STXBP5-
AS1
and EZH2 was investigated by RNA-immunoprecipitation. The binding of EZH2 on ADGB promoter was analyzed by chromatin immunoprecipitation. The methylation was quantified by bisulfite sequencing. We showed downregulation of STXBP5-
AS1
in PC associated with poor prognosis. Ectopic STXBP5-
AS1
inhibited chemoresistance and metastasis of PC cells. In addition, STXBP5-
AS1
compromised stemness of PC cells. Mechanistically, STXBP5-
AS1
potently recruited EZH2 and epigenetically regulated neighboring ADGB transcription, which predominantly mediated the inhibitory effects of STXBP5-
AS1
on stem cell-like properties of PC cells. Our study highlights the importance of the STXBP5-EZH2-ADGB axis in chemoresistance and stem cell-like properties of PC.
...
PMID:LncRNA STXBP5-AS1 suppresses stem cell-like properties of pancreatic cancer by epigenetically inhibiting neighboring androglobin gene expression. 3316 Apr 11
<< Previous
1
2
3
